MarketCap
Facebook
X
TelegramQuarterly report 2022-Q4
added 02-09-2023
Quotient Limited Cash and Cash Equivalents 2011-2026 | QTNT
Annual Cash and Cash Equivalents Quotient Limited
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 45.7 M | 3.4 M | 4.1 M | 20.2 M | 4.75 M | 44.1 M | 37.5 M | 7.19 M | 4.22 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 45.7 M | 3.4 M | 19 M |
Quarterly Cash and Cash Equivalents Quotient Limited
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.9 M | 24.5 M | 46.2 M | 65.1 M | 85.1 M | 121 M | 115 M | 115 M | 3.4 M | 3.4 M | 18.1 M | 7.32 M | 4.66 M | 4.66 M | 5.82 M | 6.53 M | 4.47 M | 4.47 M | 3.56 M | 20.2 M | 6.15 M | 9.13 M | 13 M | 4.75 M | 14.3 M | 19 M | 22.4 M | 44.1 M | 24.1 M | 25.7 M | 21.3 M | 37.5 M | 33 M | 17.1 M | 32 M | 7.19 M | 13.8 M | 1.54 M | 1.74 M | 4.22 M | - | - | - | 4.35 M | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 121 M | 1.54 M | 25 M |
Cash and Cash Equivalents of other stocks in the Diagnostics research industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
19.1 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
59.4 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Bioventus
BVS
|
51.2 M | $ 8.93 | 0.62 % | $ 595 M |  USA |
 |
Aspira Women's Health
AWH
|
13.3 M | - | -6.19 % | $ 10.5 M | USA |
 |
Brainsway Ltd.
BWAY
|
69.3 M | $ 13.54 | -0.81 % | $ 99.4 M |  Israel |
 |
Castle Biosciences
CSTL
|
120 M | $ 26.01 | 0.68 % | $ 722 M | USA |
 |
DexCom
DXCM
|
918 M | $ 68.14 | 2.71 % | $ 26.6 B | USA |
 |
Charles River Laboratories International
CRL
|
214 M | $ 153.97 | 1.32 % | $ 7.63 B | USA |
 |
CareDx, Inc
CDNA
|
65.4 M | $ 17.49 | 0.98 % | $ 932 M | USA |
 |
Guardant Health
GH
|
378 M | $ 87.81 | 0.72 % | $ 11 B | USA |
 |
Accelerate Diagnostics
AXDX
|
34.9 M | - | -61.36 % | $ 2.46 M | USA |
 |
Exact Sciences Corporation
EXAS
|
956 M | $ 103.91 | 0.06 % | $ 19.6 B | USA |
 |
Global Cord Blood Corporation
CO
|
6.66 B | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
11.7 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
176 M | - | 0.12 % | $ 80.1 M | China |
 |
Fulgent Genetics
FLGT
|
55.1 M | $ 15.53 | 3.88 % | $ 470 M | USA |
|
Biodesix
BDSX
|
26.2 M | $ 16.43 | -4.97 % | $ 2.13 B | USA |
 |
ICON Public Limited Company
ICLR
|
752 M | $ 99.67 | 2.11 % | $ 8.22 B |  Irlanda |
 |
Anixa Biosciences
ANIX
|
1.24 M | $ 2.87 | 1.06 % | $ 93.1 K | USA |
 |
IQVIA Holdings
IQV
|
1.98 B | $ 167.94 | 1.91 % | $ 28.9 B | USA |
 |
Danaher Corporation
DHR
|
4.62 B | $ 195.04 | 1.91 % | $ 139 B | USA |
 |
Biocept
BIOC
|
12.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
Heska Corporation
HSKA
|
157 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
12.2 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
1.13 B | $ 121.88 | 2.18 % | $ 19.4 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
420 M | $ 198.1 | -0.43 % | $ 22 B | USA |
 |
QIAGEN N.V.
QGEN
|
598 M | - | - | $ 10.6 B |  Niderland |
 |
Agilent Technologies
A
|
1.48 B | $ 113.81 | 1.77 % | $ 34.6 B | USA |
 |
BioNano Genomics
BNGO
|
9.17 M | $ 1.13 | 1.69 % | $ 1.44 M | USA |
 |
DarioHealth Corp.
DRIO
|
36.8 M | $ 9.28 | 10.24 % | $ 263 M | Israel |
 |
NeoGenomics
NEO
|
160 M | $ 8.3 | 0.67 % | $ 1.06 B | USA |
 |
Neogen Corporation
NEOG
|
129 M | $ 9.2 | 0.93 % | $ 2 B | USA |
 |
Lantheus Holdings
LNTH
|
359 M | $ 78.55 | 0.06 % | $ 5.3 B | USA |
 |
Chembio Diagnostics
CEMI
|
18.2 M | - | 0.22 % | $ 16.8 M | USA |
 |
Pacific Biosciences of California
PACB
|
63.7 M | $ 1.41 | 3.68 % | $ 423 M | USA |
 |
Check-Cap Ltd.
CHEK
|
7.7 M | - | - | $ 9.42 M | Israel |
 |
Co-Diagnostics
CODX
|
14.9 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Medpace Holdings
MEDP
|
497 M | $ 453.81 | 0.04 % | $ 13.1 B | USA |
 |
Motus GI Holdings
MOTS
|
4.96 M | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
66.9 M | $ 1 213.99 | 1.24 % | $ 25 B |  Schweiz |
 |
Celcuity
CELC
|
22.5 M | $ 113.65 | -1.09 % | $ 4.48 B | USA |
 |
DermTech
DMTK
|
36.7 M | - | -11.32 % | $ 2.94 M | USA |
 |
National Research Corporation
NRC
|
4.14 M | $ 17.53 | 0.75 % | $ 392 M | USA |
 |
Invitae Corporation
NVTA
|
257 M | - | - | $ 21.2 M | USA |
 |
Enzo Biochem
ENZ
|
52.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Natera
NTRA
|
466 M | $ 199.0 | 0.67 % | $ 19.6 B | USA |
 |
OPKO Health
OPK
|
427 M | $ 1.2 | 0.42 % | $ 833 M | USA |